PATENT CLAIM ANALYSIS

Application Number: 15743560
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "04400A"]

Abstract:
The invention provides methods of treating polyglutamine diseases, e.g., spinocerebellar ataxia Type 6, in a subject, comprising administering to the subject an IRES inhibitor in an amount effective for treating the SCA6 in the subject. Also provided herein are the IRES inhibitors, and pharmaceutical compositions comprising the same.

Claim (Index 38):
The pharmaceutical composition of any one of  claims 33  to  37 , wherein the antisense molecule is an antisense nucleic acid analog comprising the base sequence of SEQ ID NO: 179.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 86.0
- Lexical Diversity: 1.44737
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15024492', '15573417', '14011539', '12963793', '15508857']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6920692464043829
- 35 USC 102 Novelty (BERT): 0.5660585490244138
- Combined Prediction Score: 0.679468176666386
- Mean Citation Score: 302.607136
- Max Citation Score: 497.57776
- Similarity Product: 296.11646614007003

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test